AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Selective Janus Kinase Inhibitors for Autoimmune Disease

Summary

Researchers at Purdue University have developed a series of molecules, based on a new JAK inhibitor scaffold, that display selective inhibition for different members of the Janus kinase family. One particular compound, designed for high potency and stability, exhibits very good activity and selectivity against JAK1, with 3.3 nM activity and 10 fold and 30 fold selectivity versus JAK2 and JAK3, respectively. These new inhibitors promise to give relief to sufferers of psoriasis, myelofibrosis, rheumatoid arthritis, and other autoimmune diseases with a reduction in side effects compared to current therapies.

Technology Benefits

Reduce side effectsAllow for more options in treatments

Technology Application

Treatment of autoimmune diseases

Detailed Technology Description

Mark CushmanPurdue Medicinal Chemistry and Molecular Pharmacology

Countries

United States

Application No.

None

Country/Region

USA

For more information, please click Here